Drug |
Category |
Indication |
Comments |
|
[new]
5-AMINOLAEVULINIC ACID GEL (Ameluz®) |
 |
Actinic keratosis |
|
| ABATACEPT |
 |
Rheumatoid arthritis |
Supported only in line with NICE TA 195 |
| ACAMPROSATE |
 |
Alcohol dependence |
|
|
[new]
ACENOCOUMAROL |
|
Anticoagulation |
New patients only.
|
| ACENOCOUMAROL |
|
Anticoagulation |
For patients currently being treated with phenindione. |
| ACETYLCYSTEINE |
 |
Usual interstitial pneumonitis (UIP) |
Simple SCA |
| ACITRETIN |
|
|
|
|
[new]
ACLIDINIUM INHALER 322 micrograms (Eklira Genuair®) |
|
COPD |
|
| ACTIKERALL |
|
Actinic keratoses |
|
| ADALIMUMAB |
|
Rheumatoid and psoriatic arthritis; ankylosing spondylitis; refractory Crohn's disease |
Added indication: Refractory Crohn's disease |
| ADAPALENE / BENZOYL PEROXIDE (Epiduo®) |
|
Acne vulgaris |
|
| ADEFOVIR |
|
|
|
| Adios® |
|
Herbal slimming aid |
|
|
[new]
AFLIBERCEPT (Eylea®) |
|
Wet age related macular degeneration |
|
| Age-Related Macular Degeneration - Dietary Supplements |
|
Age-related macular degeneration (AMD) |
Not approved by local committee see Guideline |
| AGOMELATINE |
|
Depression |
Full SCA |
ALENDRONIC ACID +
VITAMIN D |
|
Postmenopausal osteoporosis |
|
| ALFENTANIL |
|
Palliative Care |
Conditional on recommendation from palliative care / renal team. See the Palliative Care Guidelines |
| ALISKIREN |
|
Hypertension
|
Full SCA |
| AMANTADINE |
|
Parkinson's disease |
Simple SCA
Third-line treatment |
| AMIFAMPRIDINE (Firdapse®) |
|
Lambert-Eaton myasthenic syndrome |
|
|
[new]
AMISULPRIDE |
|
Schizophrenia |
Full SCA |
| ANAGRELIDE |
|
|
|
| ANAKINRA |
|
|
|
| ANASTROZOLE |
|
Adjuvant therapy in early breast cancer |
Simple SCA
|
| ANIDULAFUNGIN |
|
Invasive candidiasis |
|
| ANTICANCER DRUGS |
|
Neoplastic disease |
Classified as BLACK or RED unless an exception for shared care (see this list). |
| ANTIPSYCHOTICS-Atypical |
|
Schizophrenia |
Full SCA |
| ANTIRETROVIRALS |
|
HIV |
|
| ANTITHROMBIN recombinant |
|
Congenital antithrombin deficiency |
|
|
[new]
APIXABAN (Eliquis®) |
|
Stroke and systemic embolism in non-valvular AF |
|
| APOMORPHINE |
|
Parkinson's disease |
|
| APRACLONIDINE |
|
|
|
|
[new]
ARIPIPRAZOLE |
|
Schizophrenia |
Full SCA |
| ASENAPINE |
|
Manic episodes of bipolar disorder. |
|
| ATOMOXETINE |
|
Attention deficit hyperactivity disorder (ADHD) |
Full SCA - adults
& children/adolescents |
| ATOVAQUONE |
|
|
|
| AZATHIOPRINE |
|
Inflammatory Bowel Disease (Ulcerative Colitis, Crohn’s Disease) & Autoimmune Hepatitis |
Full SCA |
| AZILSARTAN |
|
Hypertension |
|
| AZTREONAM |
|
Infection in cystic fibrosis |
|
| BECAPLERMIN |
|
|
|
| BECLOMETASONE DIPROPIONATE / FORMOTEROL (Fostair®) |
|
Asthma |
Recommend second line after Symbicort® or for pts already taking the separate components in an MDI. |
| BECLOMETASONE Inhaler - CFC free |
|
Asthma |
QVAR brand recommended for adults. Clenil Modulite brand recommended only for children. |
| BETAMETHASONE plaster (Betesil®) |
|
Inflammatory skin disorders not responding to less potent corticosteroids |
Not approved by local committee |
| BICALUTAMIDE |
|
Prostate cancer |
Simple SCA |
| BILASTINE |
|
Allergic rhinoconjunctivitis and urticaria |
|
|
[new]
BIMATOPROST preservative free eye drops (Lumigan UD®) |
|
Glaucoma |
|
|
[new]
BIOBRAN MGN-3 |
|
Adjuvant to cancer treatment |
Cancer Research UK statement |
| Bio-Oil® |
|
Skincare product |
|
| BOTULINUM A TOXIN |
|
Various indications |
see TAS website |
|
[new]
BOTULINUM TOXIN |
|
Chronic migraine |
see NICE TA |
| BRINZOLAMIDE / TIMOLOL (Azarga®) |
|
Glaucoma |
Not approved by local committee |
| BUPRENORPHINE |
|
Severe pain |
including transdermal patch |
| CABERGOLINE |
|
Parkinson's disease |
Simple SCA
Second Line Treatment |
| CALCITONIN injection |
|
|
SCA to be developed. Existing primary care prescribing to continue. |
| CANNABIS Derivative (Sativex) |
|
Multiple sclerosis |
see East Midlands policy |
| CAPSAICIN 8% patch (Qutenza) |
|
Peripheral neuropathic pain |
Only if unresponsive to other treatments in local guidance. |
| CASPOFUNGIN |
|
|
|
| CEFIXIME |
|
Gonorrhoea |
|
| CEFOTAXIME |
|
|
|
|
[new]
CEFTAROLINE FOSAMIL (Zinforo®) |
|
Complicated skin and soft tissue infections, community acquired pneumonia |
5th generation cephalosporin |
| CEFTAZIDIME |
|
|
|
| CELECOXIB (Onsenal®) |
|
Familial adenomatous polyposis |
|
| CERTOLIZUMAB PEGOL |
|
Rheumatoid arthritis |
Supported by NICE - see NICE Technology Appraisal TA186 |
| CHLORHEXIDINE GLUCONATE cream (Eczmol®) |
|
Eczema and Dermatitis |
Not approved by local committee |
| CHORIONIC GONADOTROPHIN |
|
|
|
| Cica-Care® |
|
Hypertrophic Scars |
Full SCA
|
| CICLOSPORIN oral |
|
Dermatology |
SCA to be developed. Existing primary care prescribing to continue. |
| CICLOSPORIN oral |
|
Immunosuppression |
SCA to be developed. Existing primary care prescribing to continue. |
| CIDOFOVIR |
|
CMV retinitis |
|
| CINACALCET |
|
Secondary hyperparathyroidism |
Full SCA
|
|
[new]
CINNARIZINE / DIMENHYDRINATE (Arlevert®) |
|
Meniere's disease |
|
| CIPROFLOXACIN eye ointment |
|
Eye infections |
Second-line to chloramphenicol |
| CLOMIPHENE |
|
|
|
| CLOZAPINE |
|
|
Leicestershire Partnership Trust consultants only |
|
[new]
COLISTIMETHATE SODIUM (Colobreathe®) INHALATION POWDER |
|
Cystic Fibrosis |
|
| COLISTIN |
|
IV for cystic fibrosis |
|
| COLISTIN |
|
Pseudomonas aeruginosa lung infections (Nebulised)
|
Full SCA (Colomycin)
Full SCA Promixin |
| DABIGATRAN |
|
Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation |
Full SCA |
| DABIGATRAN |
|
Prevention of Venous Thromboembolism (VTE) following knee / hip replacement surgery |
Supported by NICE - see NICE Technology Appraisal TA157 |
| DALTEPARIN |
|
Thromboprophylaxis & treatment of DVT |
If prescriber has not received training. Full SCA |
| DALTEPARIN |
|
Thromboprophylaxis and Treatment of DVT |
Conditional for those prescribers who have received the accredited training currently used in One City.Training |
|
[new]
DAPAGLIFLOZIN (Forxiga®) |
|
Type 2 diabetes |
|
| DAPTOMYCIN |
|
Complicated Gram +ve skin/soft tissue infections |
|
| DARBEPOETIN |
|
Anaemia of chronic kidney disease |
|
| DARIFENACIN |
|
Urinary incontinence/urgency |
|
| DARUNAVIR |
|
HIV infection |
|
| DEFERASIROX |
|
Iron overload |
|
| DEFERIPRONE |
|
|
|
| DEGARELIX |
|
Treatment of prostate cancer |
Full SCA |
|
[new]
DENOSUMAB |
|
Osteoporosis |
Simple SCA |
|
[new]
DENOSUMAB (Xgeva®) |
|
Prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate |
Red for patients with severe renal impairment (creatinine clearance less than 30ml/min) |
|
[new]
DENOSUMAB (Xgeva®) |
|
Prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate |
Simple SCA |
| Dermatix® |
|
Dressing for treatment of scars |
|
| DESFERRIOXAMINE |
|
|
|
| DESIRUDIN |
|
|
|
| DEXAMETHASONE intravitreal implant |
|
Macular oedema due to retinal vein occlusion |
See NICE TA 229 |
| DEXAMFETAMINE |
|
Attention deficit hyperactivity disorder (ADHD) |
Full SCA - adults
& children/adolescents< |
| DEXIBUPROFEN |
|
Pain and inflammation |
|
| DICLOFENAC GEL 3% (Solaraze®) |
|
Actinic keratosis |
|
| DINOPROSTONE |
|
Induction of labour |
|
| DISODIUM PAMIDRONATE |
|
|
|
|
[new]
DISULFIRAM |
|
Adjunct in alcohol dependence |
Existing prescribing in primary care to continue. SCA under development |
| DOLASETRON |
|
Chemotherapy-induced nausea & vomiting |
|
| DONEPEZIL |
|
|
Leicestershire Partnership Trust consultants only |
| DORIPENEM |
|
Nosocomial pneumonia, complicated intra-abdominal and urinary tract infection |
|
| DORIPENEM |
|
Hospital acquired/ventilator associated pneumonia |
|
| DORNASE ALFA |
|
Cystic fibrosis |
Simple SCA |
| DOXYCYCLINE Controlled release (Efracea®) |
|
Rosacea |
Not approved by local committee |
| DRONEDARONE |
|
Atrial fibrillation
Existing patients already on treatment.
|
Full SCA
See also NICE Technology Appraisal TA19 |
| DRONEDARONE |
|
Atrial fibrillation |
New patients |
| DROPERIDOL |
|
Post operative nausea & vomiting |
3rd line |
| DULOXETINE |
|
Stress incontinence |
|
| DULOXETINE |
|
Diabetic neuropathy |
To be used in conjunction with Neuropathic Pain Guidelines |
| DUTASTERIDE / TAMSULOSIN (Combodart®) |
|
Benign Prostatic Hyperplasia when used in line with pathway
|
Green if prescribed in line with local Algorithm for treatment
|
| ECZEMOL |
|
Eczema |
Adjunctive therapy for decreasing bacterial load only in cases of recurrent infected atopic eczema in children. |
| EFALIZUMAB |
|
|
|
| EFAVIRENZ |
|
|
|
| EFLORNITHINE |
|
Female facial hirsuitism |
Not approved by local committee |
| ELTROMBOPAG |
|
Chronic immune (idiopathic) thrombocytopenic purpura (ITP) |
|
| ENTACAPONE |
|
Parkinson's disease |
Simple SCA |
| ENTECAVIR |
|
Chronic hepatitis B |
|
| EPLERENONE |
|
Post myocardial infarction with proven LVH |
Full SCA |
| EPOETIN DELTA |
|
Anaemia of renal failure |
|
| EPOETIN intravenous |
|
|
HDU |
| EPOETIN subcutaneous |
|
Anaemia of Chronic Kidney Disease |
|
| EPOPROSTENOL |
|
|
|
| ERDOSTEINE |
|
Mucolytic - acute exacerbation of chronic bronchitis |
Not approved by local committee |
| ERTAPENEM |
|
Resistant Gram negative infections (ESBL) |
|
| ESCITALOPRAM |
|
All indications except MDD |
Not approved by local committee |
| ESCITALOPRAM |
|
Major Depressive Disorder (MDD) |
Simple SCA |
| ESLICARBAZEPINE |
|
Treatment resistant epilepsy |
|
|
[new]
ESTRADIOL/NOMEGESTROL (Zoely®) |
|
Combined oral contraceptive |
|
| ETANERCEPT |
|
DMARD for RA, including weekly SC injection |
|
| ETANERCEPT |
|
Plaque psoriasis |
In line with NICE TA103 |
| EVRA® patch |
|
Contraception |
|
| EXEMESTANE |
|
Adjuvant therapy in early breast cancer |
Simple SCA
See also LNRC |
| EXENATIDE with/without INSULIN |
|
Type 2 diabetes |
Conditional on prescriber being trained to select and train patients - Use in conjunction with Updated NICE Clinical Guideline |
| EXENATIDE with/without INSULIN |
|
Type 2 Diabetes |
If prescriber has not received specific training. Full SCA |
| EZETIMIBE |
|
|
|
| EZETIMIBE + SIMVASTATIN (Inegy) |
|
Hypercholesterolaemia |
|
|
[new]
FAMPRIDINE |
|
Multiple Sclerosis |
|
|
[new]
FEBUXOSTAT |
|
Gout (2nd line after allopurinol) |
in line with NICE TA |
| FENTANYL intranasal spray |
|
Breakthrough cancer pain |
|
| FENTANYL Sublingual (Abstral®) |
|
Breakthrough cancer pain in patients already on opioids |
Conditional on recommendation from palliative care team. see the Palliative Care Guidelines |
| FENTICONAZOLE |
|
Vulvovaginal candidiasis |
|
|
[new]
FERUMOXYTOL INJECTION (Rienso®) |
|
Iron deficiency anaemia in chronic kidney disease |
|
| FESOTERODINE |
|
Urinary frequency |
|
| FILGRASTRIM |
|
|
|
|
[new]
FINGOLIMOD |
|
Multiple Sclerosis |
NICE supported.
EMSCG funding. |
| FLUNARAZINE |
|
Alternating hemiplegia/refractory migraine in children |
Unlicensed |
|
[new]
FLUOCINOLONE ACETONIDE intravitreal implant |
|
Diabetic macular oedema |
|
| FLUPENTIXOL DECANOATE |
|
Schizophrenia |
Full SCA |
| FLUPHENAZINE DECANOATE |
|
Schizophrenia |
Full SCA |
| FLUTICASONE FUROATE (Avamys®) |
|
Allergic rhinitis |
|
|
[new]
FLUTICASONE/FORMOTEROL (Flutiform®) |
|
Asthma |
Reviewed by Leicestershire and Rutland Respiratory Prescribing Group April 2013 |
| FOLLITROPHIN alfa/beta |
|
|
|
| FONDAPARINUX |
|
Heparin Induced Thrombocytopaenia (HIT) |
|
|
[new]
FULVESTRANT |
|
Oestrogen receptor positive metastatic or locally advanced breast cancer in post menopausal women in whom disease progresses or relapses while on or after other anti oestrogen therapy |
SCA to be developed. Red for new patients until SCA in place. Existing prescribing in primary care to continue. |
| GABAPENTIN |
|
Neuropathic pain |
To be used in conjunction with Neuropathic Pain Guidelines |
| GALANTAMINE |
|
Alzheimer’s disease |
Leicestershire Partnership Trust consultants only |
| GAMMAGLOBULIN |
|
|
|
| GANCICLOVIR |
|
|
|
| GENTAMICIN |
|
IV and inhalation |
|
| GLATIRAMER |
|
Multiple sclerosis |
Not supported by NICE but supported by DoH. |
| GLUCOSAMINE |
|
Osteoarthritis |
Guidelines |
| GLYCERYL TRINITRATE Ointment 0.4% |
|
Anal fissure |
|
| GLYCOPROTEIN IIb/IIIa inhibitors |
|
|
|
|
[new]
GLYCOPYRRONIUM INHALER (Seebri Breezhaler®) |
|
COPD |
|
| GOLD salts |
|
DMARD for RA |
SCA to be developed. Existing primary care prescribing to continue. |
| GOLIMUMAB |
|
Psoriatic arthritis (PA) and Rheumatoid arthritis(RA)in line with NICE guidance |
PA see NICE TA 220
RA see NICE TA 225 |
| GOLIMUMAB |
|
Ankylosing spondylitis |
|
| GONADORELIN ANALOGUES |
|
Prostate cancer |
In patients in whom anti-androgen treatment has been started by secondary care clinician. |
| GONADOTROPHIN |
|
|
|
| GOSERELIN |
|
Endometriosis, uterine fibroids |
Simple SCA |
| GOSERELIN |
|
Prostatic carcinoma |
|
| GRANISETRON |
|
Chemotherapy-induced nausea |
|
| GRASS POLLEN ALLERGEN EXTRACT (Grazax®) |
|
Grass pollen allergies |
Full SCA |
|
[new]
HALOPERIDOL DECANOATE |
|
Schizophrenia |
Full SCA |
| HEPATITIS C treatments |
|
|
|
| HOMEOPATHIC MEDICINES |
|
|
Not approved by local committee see Position Statement |
|
[new]
HYDROCORTISONE modified release (Plenadren®) |
|
Hypoadrenalism (once daily dose)
|
|
| HYDROXYCARBAMIDE |
|
Myeloproliferative disorders |
Full SCA |
| HYDROXYCHLOROQUINE |
|
Rheumatoid arthritis |
Full SCA |
| IBANDRONIC ACID - IV |
|
Postmenopausal osteoporosis |
|
| IBANDRONIC ACID - Oral |
|
Breast cancer bone metastases |
Simple SCA |
| IBANDRONIC ACID Oral monthly |
|
Postmenopausal osteoporosis |
Use only when compliance with oral therapy is an issue |
| ICATIBANT acetate |
|
Hereditary angioedema |
Not approved by local committee |
| IDURSULFASE |
|
Hunter syndrome (mucopolysaccharidosis II) |
|
| IMIPENEM |
|
|
|
|
[new]
IMIQUIMOD CREAM 3.75% (Zyclara®) |
|
Actinic keratosis of face and scalp
|
|
| IMMUNOGLOBULINS |
|
|
|
| INDACATEROL (Breezhaler®) |
|
COPD |
Not approved by local committee |
| INFLIXIMAB |
|
All indications |
|
|
[new]
INGENOL MEBUTATE GEL (Picato®) |
|
Actinic keratosis (non hypertrophic)
|
|
|
[new]
INSULIN DEGLUDEC (Tresiba®) |
|
Type 1 and type 2 diabetes |
100 and 200 units/ml injection |
| INSULIN GLULISINE (Apidra®) |
|
Type 1 and 2 diabetes |
Prescribe by brand name to avoid confusion with insulin glargine. |
| INTERFERON ALFA |
|
|
|
| INTERFERON BETA |
|
|
|
| ISOTRETINOIN - Oral |
|
Severe acne |
|
| ISOTRETINOIN - Topical |
|
Mild-moderate acne |
|
| IVABRADINE |
|
Chronic stable angina |
For patients who cannot tolerate beta blockers |
|
[new]
IVABRADINE |
|
Chronic heart failure |
Simple SCA |
|
[new]
IVACAFTOR |
|
Cystic fibrosis |
|
| Kelo-cote® |
|
Hypertrophic Scars |
Full SCA
|
| KETAMINE |
|
Palliative Care |
Conditional on recommendation from palliative care team. Normally started in secondary care setting. See the Palliative Care Guidelines |
| KETOPROFEN / OMEPRAZOLE (Axorid®) |
|
Pain and inflammation for patients at risk of NSAID associated ulcers |
|
| KETOROLAC |
|
Palliative Care |
Conditional on recommendation from palliative care team. See the Palliative Care Guidelines |
| LACOSAMIDE |
|
Resistant epilepsy |
Simple SCA |
| LANREOTIDE |
|
Neuroendocrine tumours |
Simple SCA |
| LANREOTIDE |
|
Acromegaly |
SCA to be developed. Existing primary care prescribing to continue. |
| LANREOTIDE |
|
Palliative Care |
Conditional on recommendation from palliative care team. See the Palliative Care Guidelines |
| LANTHANUM CARBONATE |
|
Hyperphosphataemia with renal failure |
Simple SCA |
|
[new]
LATANOPROST preservative free eye drops (Monopost®) |
|
Glaucoma |
|
| LEFLUNOMIDE |
|
DMARD for rheumatoid arthritis |
FULL SCA |
| LENOGRASTIM |
|
|
|
| LETROZOLE |
|
Adjuvant therapy in early breast cancer |
Simple SCA
See also LNRC |
| LEUPRORELIN |
|
Prostate cancer |
Subcutaneous injection for patients at risk of haematoma |
| LEUPRORELIN |
|
Endometriosis, uterine fibroids |
Simple SCA |
| LEVETIRACETAM - IV |
|
Epilepsy |
Restricted to patients who are already maintained on the oral preparation |
| LEVETIRACETAM - Oral |
|
Epilepsy |
Simple SCA |
| LEVODOPA/CARBIDOPA infusion (Duodopa) |
|
Parkinson's disease |
|
| LEVOFLOXACIN Eyedrops - unpreserved |
|
Bacterial keratitis |
|
| LIDOCAINE patch |
|
Focal neuropathic pain |
To be used in conjunction with Neuropathic Pain Guidelines |
| LIDOCAINE patch |
|
Postherpetic neuralgia |
To be used in conjunction with Neuropathic Pain Guidelines |
|
[new]
LINACLOTIDE (Constella®) |
|
Moderate to severe irritable bowel syndrome with constipation |
|
|
[new]
LINAGLIPTIN |
|
Type 2 Diabetes |
|
|
[new]
LINAGLIPTIN/METFORMIN (Jentadueto®) |
|
Type II diabetes where metformin alone inadequate |
|
| LIRAGLUTIDE |
|
For weight loss |
|
| LIRAGLUTIDE |
|
Type 2 diabetes |
If prescriber has not received training.Full SCA |
| LIRAGLUTIDE |
|
Type 2 diabetes |
For patients unable to tolerate nausea with exenatide. Conditional on prescriber being trained to select and train patients - Use in conjunction with Updated NICE Clinical Guideline |
|
[new]
LIRAGLUTIDE plus INSULIN |
|
Diabetes |
Unlicensed use. Decision reviewed and confirmed by TAS April 2013. |
|
[new]
LISDEXAMFETAMINE DIMESYLATE (Elvanse®) |
|
ADHD when response to methylphenidate is inadequate |
|
| LITHIUM SALTS |
|
Mania, Bipolar Disorder, Recurrent Depression or Aggressive or Self-mutilating behaviour. |
Full SCA |
|
[new]
MANNITOL dry powder inhaler |
|
Cystic fibrosis |
|
|
[new]
MEDROXYPROGESTERONE ACETATE DEPOT INJECTION (Sayana Press®) |
|
Long-term contraception |
|
| MELATONIN |
|
Sleep onset insomnia and delayed sleep phase syndrome in children, continued in adults if proven efficacy in childhood |
Simple SCA
See also LMSG guidelines |
| MELATONIN |
|
Primary insomnia in adults |
|
| MEMANTINE |
|
Alzheimer’s disease |
|
| MENOTROPHIN |
|
|
|
| Mepiform® |
|
Hypertrophic Scars |
Full SCA
|
| MERCAPTOPURINE |
|
Inflammatory Bowel Disease (Ulcerative Colitis, Crohn’s Disease) & Autoimmune Hepatitis |
Full SCA |
| MEROPENEM |
|
|
|
| MESALAZINE |
|
Crohn's disease |
Including Salofalk® granules in children.
Sustained-release formulation (Mezavant® XL) is BLACK - not supported by UHL TAS |
| METHADONE 10mg/1ml |
|
All indications |
This is to prevent dosing errors. The 1mg/1ml strength remains available. |
| METHADONE 1mg/1ml |
|
Palliative Care |
Conditional on recommendation from palliative care team. See the Palliative Care Guidelines |
| METHOTREXATE Injection |
|
|
|
| METHOTREXATE Oral |
|
Rheumatoid arthritis |
Full SCA |
| METHOTREXATE oral |
|
Psoriasis |
|
| METHYLNATREXONE |
|
Opioid-induced constipation in advanced illness in patients receiving palliative care |
Conditional on recommendation from palliative care team. See the Palliative Care Guidelines |
| METHYLPHENIDATE (+ ‘CR’) |
|
Attention deficit hyperactivity disorder (ADHD) |
Full SCA - adults
& children/adolescents |
|
[new]
MEXILETINE |
|
Ventricular arrhythmia |
New patients. Existing prescribing in primary care to continue. |
| MIANSERIN |
|
Depression |
Full SCA |
| MIDAZOLAM (Buccal) |
|
Status epilepticus |
Simple SCA |
| MIDAZOLAM buccal |
|
Palliative Care |
Conditional on recommendation from palliative care team. See the Palliative Care Guidelines |
| MIFEPRISTONE |
|
|
|
| MIGLUSTAT |
|
Niemann-Pick type C disease |
|
|
[new]
MIRABEGRON (Betmiga®) |
|
Symptoms of urinary frequency, urgency and urge incontinence |
|
| MODAFINIL |
|
Daytime sleepiness associated with Narcolepsy and existing patients being treated for Daytime Sleepiness associated with Obstructive Sleep Apnoea Syndrome, Idiopathic Hypersomnia & Shift Work Sleep Disorder. |
Full SCA |
| MOLOGRAMOSTIN |
|
|
|
| MOVICOL liquid |
|
Constipation |
|
| MOXIFLOXACIN |
|
Multi-drug resistant tuberculosis |
|
| MOXIFLOXACIN |
|
Respiratory tract infections (general) |
|
|
[new]
MYCOPHENOLATE |
|
Immunosuppression following renal transplantation |
Full SCA |
| NABILONE |
|
|
|
| NALTREXONE |
|
Pruritus in liver disease |
Unlicensed indication |
| NAPROXEN / ESOMEPRAZOLE (Vimovo®) |
|
Osteoarthritis, RA & ankylosing spondylitis |
|
| NATALIZUMAB |
|
Rapidly evolving relapsing-remitting multiple sclerosis |
|
| NEBIVOLOL |
|
Hypertension |
Black for all other indications |
| NEBIVOLOL |
|
All indications excluding hypertension (Green) |
|
|
[new]
NICOTINIC ACID / LAROPIPRANT (Tredaptive®) |
|
Product license withdrawn January 2013, contact Medicines Management for advice |
|
| NUVARING® |
|
Contraception |
|
| OCTREOTIDE |
|
Palliative Care |
Conditional on recommendation from palliative care team. See the Palliative Care Guidelines |
| OCTREOTIDE |
|
GEP tumours and post-pancreatic surgery |
|
| OCTREOTIDE |
|
Acromegaly |
SCA to be developed. Existing primary care prescribing to continue. |
|
[new]
OLANZAPINE |
|
Schizophrenia, mania |
Full SCA |
| OLANZAPINE PAMOATE MONOHYDRATE (Zypadhera®) |
|
Schizophrenia |
Requires case by case consideration by Prescribing Group |
| OLOPATADINE |
|
Hay fever |
|
| OMACOR® |
|
Secondary prevention of MI |
Contains Omega-3 acid ethyl esters |
| OMACOR® |
|
Hypertriglyceridaemia |
Simple SCA
|
| OMALIZUMAB |
|
Asthma |
|
|
[new]
ONDANSETRON |
|
Hyperemesis in pregnancy
Chemotherapy/radiotherapy induced nausea |
|
| ORLISTAT |
|
|
|
| OXYBUTYNIN patch |
|
Symptomatic treatment of urge incontinence in unstable bladder |
No longer a formulary choice SeeGuidelines for Antimuscarinic Drugs |
| OXYCODONE / NALOXONE (Targinact®) |
|
Severe pain in patients with opioid-induced bowel dysfunction |
Simple SCA |
|
[new]
PALIPERIDONE PALMITATE Long-Acting Injection |
|
Schizophrenia for patients showing previous response to risperidone oral or IM |
Full SCA |
| PALIVIZUMAB |
|
|
|
| PALONOSETRON |
|
Nausea and vomiting with chemotherapy |
|
| PARACALCITOL |
|
Secondary hyperparathyroidism in renal failure |
|
| PENICILLAMINE |
|
DMARD for RA |
SCA to be developed. Existing primary care prescribing to continue. |
|
[new]
PERAMPANEL (Fycompa®) |
|
Refractory epilepsy |
|
| PERGOLIDE |
|
Parkinson's disease |
Simple SCA
Second-line treatment |
| PIMECROLIMUS cream |
|
Dermatitis |
|
|
[new]
PIPOTIAZINE PALMITATE |
|
Schizophrenia |
Full SCA |
| POSACONAZOLE |
|
Severe fungal infections |
|
| PRAMIPEXOLE |
|
Parkinson's disease |
Simple SCA |
| PRAMIPEXOLE |
|
Restless legs and other leg movement disorders |
Full SCA |
| PRASUGREL |
|
ACS where immediate primary percutaneous coronary intervention for ST segment-elevation MI is necessary or stent thrombosis has occurred during clopidogrel treatment. |
Excludes pts over 75yrs and /or weight less than 60kg. Black for all indications not under SCA. Simple SCA |
| PREGABALIN |
|
Neuropathic pain |
To be used in conjunction with Neuropathic Pain Guidelines |
| PREGABALIN |
|
Generalised anxiety disorder |
Simple SCA |
| PREGABALIN |
|
Refractory epilepsy |
Simple SCA |
|
[new]
PRO-SIL® Silicone gel |
|
Keloid and hypertrophic scar dressing |
|
| PRUCALOPRIDE |
|
Chronic refractory constipation in women |
Simple SCA |
| PYRIDOSTIGMINE |
|
Myasthenia gravis |
Includes sustained release formulation (Mestinon Timespan) Simple SCA |
| QLAIRA® |
|
Contraception |
Not approved by local committee |
|
[new]
QUETIAPINE |
|
Schizophrenia, mania |
Full SCA |
| QUINAGOLIDE |
|
Hyperprolactinaemia |
Simple SCA |
|
[new]
RACECADOTRIL (Hidrasec®) |
|
Diarrhoea |
|
| RALTEGRAVIR |
|
Multi-resistant HIV |
|
|
[new]
RANIBIZUMAB (Lucentis®) |
|
Age-related macular degeneration and diabetic macular oedema |
|
| RANOLAZINE |
|
Chronic stable angina |
Simple SCA |
| RASAGILINE |
|
Parkinson’s disease |
Simple SCA |
| REPAGLINIDE |
|
|
|
| REPHOREN® |
|
Hyperphosphataemia |
|
| RESPERATE device |
|
Hypertension |
Reviewed by Dr A. Stanley, Hypertension Clinic |
| RETAPAMULIN |
|
Bacterial skin infections |
|
| RETIGABINE |
|
Treatment resistant epilepsy |
|
| RIBAVIRIN |
|
|
|
| RIFAMIXIN |
|
Traveller's diarrhoea |
|
|
[new]
RIFAXIMIN (Targaxan®) |
|
Reduction in recurrence of hepatic encephalopathy
|
|
| RILUZOLE |
|
Amylotrophic lateral sclerosis |
Full SCA |
|
[new]
RISPERIDONE |
|
Psychoses, mania |
Full SCA |
|
[new]
RISPERIDONE LONG-ACTING INJECTION (Risperdal Consta®) |
|
Maintenance treatment of schizophrenia in patients currently stabilised with oral antipsychotics.
|
Full SCA |
| RITUXIMAB |
|
Lymphoma, Rheumatois arthritis |
|
| RIVAROXABAN |
|
Prevention of VTE in adults undergoing hip or knee replacement |
|
| RIVAROXABAN |
|
Venous thromboembolism (treatment and long term secondary prevention) |
Full SCA |
| RIVAROXABAN |
|
Prevention of stroke & embolism in non-valvular AF |
Full SCA |
| RIVASTIGMINE |
|
|
|
| ROFLUMILAST |
|
COPD |
|
| ROMIPLOSTIM (Nplate®) |
|
Chronic immune (idiopathic) thrombocytopenic purpura (ITP) |
|
| ROPINIROLE |
|
Restless legs and other leg movement disorders |
Full SCA |
| ROPINIROLE |
|
Parkinson's disease |
Simple SCA |
| ROSIGLITAZONE (Avandia®, Avandamet®) |
|
Withdrawn |
|
| ROSUVASTATIN |
|
Hypercholesterolaemia |
|
| ROTIGOTINE |
|
Restless legs syndome and other limb movement disorders |
Full SCA |
| ROTIGOTINE PATCH |
|
Parkinson's disease |
Simple SCA
Second-line - alternative to oral therapy if the patient has swallowing difficulties |
| RUFINAMIDE |
|
Lennox-Gastaut syndrome in patients aged over 4 years |
Simple SCA |
| SATIVEX |
|
Treatment of spasticity associated with Multiple Sclerosis |
EM Policy |
| SAXAGLIPTIN (Onglyza®) |
|
Type 2 Diabetes. |
Non-formulary choice. |
|
[new]
SAXAGLIPTIN/METFORMIN (Komboglyze®) |
|
Type 2 Diabetes |
|
| SEVELAMER |
|
Hyperphosphataemia |
Simple SCA |
| SILDENAFIL |
|
Pulmonary arterial hypertension |
|
|
[new]
SILDENAFIL ORAL SUSPENSION (Revatio®) |
|
Pulmonary artery hypertension
|
|
| SILICONE GEL / GEL SHEETS |
|
Hypertrophic Scars |
Full SCA (Only includes Kelocote, Cica-Care and Mepiform) |
|
[new]
SIROLIMUS |
|
Immunosuppression post renal transplant |
Full SCA |
| SITAGLIPTIN |
|
Type 2 diabetes |
Prescribe in line with NICE guidance only. |
| SITAGLIPTIN / METFORMIN (Janumet®) |
|
Type 2 diabetes |
|
| SITAXENTAN |
|
Pulmonary arterial hypertension |
Will be prescribed only in tertiary centres |
| SODIUM OXYBATE |
|
Treatment of cataplexy associated with narcolepsy |
Simple SCA |
| SODIUM VALPROATE SR (Episenta®) |
|
Epilepsy |
Not approved by local committee |
| SOLIFENACIN |
|
Urinary incontinence |
|
| SOMATROPIN (Growth Hormone) |
|
Growth disorders |
New patients supplied through healthcare at home |
| SUGAMMADEX |
|
Reversal of neuromuscular blockade |
Emergency use only. |
| SULFASALAZINE |
|
Bowel disorders. DMARD for rheumatoid arthritis. |
|
| SYNVISC |
|
Black in ALL indications except for Pain relief in osteoarthritis of shoulder joint |
|
|
[new]
TACROLIMUS capsules (Adoport®, Prograf® or Modigraf®) |
|
Immunosuppression post renal transplant - prescribe by brand name only as different brands are not interchangeable |
Full SCA |
| TACROLIMUS capsules (Advagraf®) |
|
Immunosuppression |
Modified-release |
| TACROLIMUS ointment |
|
Dermatitis |
|
|
[new]
TADALAFIL |
|
Benign prostatic hyperplasia |
|
| TADALAFIL (Adcirca®) |
|
Pulmonary arterial hypertension |
|
| TAMSULOSIN (Flomaxtra® XL) tablets |
|
Benign prostatic hypertrophy |
|
| TAMSULOSIN capsules |
|
Benign prostatic hypertrophy |
|
| TAPENTADOL immediate release |
|
Acute pain |
|
| TAPENTADOL sustained release |
|
Severe chronic pain |
|
| TEICOPLANIN |
|
Cellulitis (in primary care) |
To be used in conjunction with the Primary Care Cellulitis Pathway - see Class II page 5 |
| TEICOPLANIN |
|
All indications except cellulitis in primary care |
|
| TERIPARATIDE |
|
Osteoporosis |
|
| TESTOSTERONE buccal |
|
Male hyogonadism |
|
| TESTOSTERONE Patches (Intrinsa®) |
|
Hypoactive sexual desire disorder in women |
Not approved by local committee |
| TESTOSTERONE Preparations |
|
Hypogonadism |
Full SCA |
| THALIDOMIDE |
|
Multiple myeloma |
|
| TICAGRELOR |
|
Troponin positive Acute Coronary Syndromes in NSTEMI patients |
Simple SCA |
| TIGECYCLINE |
|
Skin and soft tissue infections |
|
| TIOTROPIUM |
|
COPD |
Leicestershire & Rutland Respiratory Prescribing Group do not support the use of the Respimat formulation. |
| TIPRANAVIR |
|
HIV infection |
|
| TIZANIDINE |
|
MS spasticity |
SCA to be developed. Existing primary care prescribing to continue. |
| TOBRAMYCIN inhalation |
|
Cystic fibrosis |
|
| TOBRAMYCIN injection |
|
|
|
| TOCILIZUMAB (RoActemra®) |
|
Rheumatoid arthritis |
Supported by NICE - see NICE Technology Appraisal TA198 |
| TOLCAPONE |
|
Parkinson's disease |
Specilaist only due to hepatic toxicity and monitoring |
| TOLVAPTAN (Samsca®) |
|
Hyponatraemia secondary to SIADH |
|
| TOPIRAMATE |
|
Epilepsy |
SCA to be developed. Existing primary care prescribing to continue. |
| TOPIRAMATE |
|
Migraine |
|
| TRAMADOL |
|
Severe pain |
including SR tablets |
| TRIPLE BROMIDES |
|
Intractable epileptic seizures |
Not approved by local committee |
| TRIPTORELIN |
|
Precocious puberty |
|
| TRIPTORELIN |
|
Prostatic carcinoma |
|
| TRIPTORELIN |
|
Endometriosis, uterine fibroids |
Simple SCA |
| TROSPIUM XL |
|
Urinary incontinence |
|
| UBIQUINONE Q10 |
|
Statin-induced myopathy |
Not approved by local committee |
| ULIPRISTAL ACETATE (ellaOne) |
|
Emergency contraception |
Within 72 hours (3 days) of unprotected sexual intercourse or contraceptive failure.
Use before 72 hours for patients at high risk of pregnancy restricted to Mr Oloto for trial period.
|
| ULIPRISTAL ACETATE (ellaOne) |
|
Emergency contraception |
After 72 hours (3 days) to 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure |
|
[new]
ULIPRISTAL ACETATE (Esmya®) |
|
Pre-operative treatment of uterine fibroids.
Review appropriateness of treatment after 3/12 |
Simple SCA |
| USTEKINUMAB |
|
Plaque psoriasis |
Supported by NICE |
| VALSARTAN/AMLODIPINE (Exforge®) |
|
Hypertension |
Not approved by local committee |
| VARENICLINE |
|
Smoking cessation |
Alternative option to NRT or buproprion subject to patient using accredited smoking cessation services |
| VENLAFAXINE |
|
Treatment-resistant depression - high dose (≥300mg) |
Full SCA |
| VENLAFAXINE |
|
Depression - low dose (<300mg) |
|
| VILDAGLIPTIN |
|
Type 2 diabetes |
|
| VILDAGLIPTIN / METFORMIN (Eucreas®) |
|
Type 2 diabetes |
|
| VIMOVO® (esomeprazole +naproxen) |
|
Rheumatoid arthritis, osteoarthritis and ankylosing spondylitis |
|
| VORICONAZOLE |
|
All indications - High cost drug - use on microbiologist advice only |
|
| YASMIN® |
|
Contraception |
NOTE: More expensive, with no evidence of significant advantages, compared to other similar OCs. |
| ZICONOTIDE |
|
Severe chronic pain (intrathecal) |
|
| ZOLENDRONIC ACID infusion |
|
Pagets disease & Osteoporosis |
|
| ZONISAMIDE |
|
Refractory epilepsy |
Simple SCA |
|
[new]
ZOSTAVAX (Varicella zoster vaccine) |
|
Prevention of shingles and post-herpetic neuralgia |
|
|
[new]
ZUCLOPENTHIXOL ACETATE (Clopixol Acuphase®) |
|
Short-term management of acute psychosis or mania |
|
|
[new]
ZUCLOPENTHIXOL DECANOATE (Clopixol® Depot and Clopixol® Conc.) |
|
Schizophrenia |
Full SCA |
